Beyond angiogenesis: the cardioprotective potential of fibroblast growth factor-2.
In the field of cardiovascular research, a number of independent approaches have been explored to protect the heart from acute and chronic ischemic damage. Fibroblast growth factor-2 (FGF-2) recently has received considerable attention with respect to its angiogenic potential. While therapeutic angiogenesis may serve to salvage chronically ischemic myocardium, more acute treatments are in demand to increase cardiac resistance to injury (preconditioning) and to guard against secondary injury after an acute ischemic insult. Here, we look beyond the angiogenic potential of FGF-2 and examine its acute cardioprotective activity as demonstrated under experimental conditions, both as an agent of a preconditioning-like response and for secondary injury prevention at the time of reperfusion. Factors to consider in moving to the clinical setting will be discussed, including issues of dosage, treatment duration, and routes of administration. Finally, issues of safety and clinical trial design will be considered. The prospect of such a multipotent growth factor having clinical usefulness opens the door to effective treatment of both acute and chronic ischemic heart disease, something well worth the attention of the cardiovascular community.
Detillieux
Karen A
KA
Department of Physiology, University of Manitoba, 730 William Avenue, Winnipeg, Manitoba R3E 3J7, Canada. kadetil@cc.umanitoba.ca
Cattini
Peter A
PA
Kardami
Elissavet
E
D000818:Animals; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D006331:Heart Diseases / Q000517:prevention & control*; D006801:Humans; D019157:Ischemic Preconditioning, Myocardial; D009389:Neovascularization, Pathologic / Q000517:prevention & control*
D016222:Fibroblast Growth Factor 2